2019 Clinical Trials DEA Safety 
Canna Law Blog
MAY 7, 2020
At the same time, because of the federal illegality of cannabis, the federal government has routinely denied third party requests for further research in regards to its potential medical benefits, among other health and safety impacts. As of December 2019, there are only two patients on the coveted list and no new entrants are permitted.
Canna Law Blog
NOVEMBER 6, 2021
To acknowledge its impressive safety record and potential for treating depression more effectively than existing therapies, the Food and Drug Administration designated psilocybin a breakthrough therapy in 2018 and 2019 for treating drug-resistant depression and major depressive disorder. For two decades, U.S.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
APRIL 8, 2022
This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. Later that year, Doblin sued the DEA for the first time. Rick Doblin, Ph.D., and Michael Mithoefer, M.D., Lyle Craker, Ph.D.,
Cannabis Law Report
MAY 29, 2022
In May 2019, Denver became the first city to decriminalize psilocybin, followed by Oakland, CA, Washington, D.C., In 2019, FDA approved Spravato (esketamine) nasal spray for treatment of depression in adults. [8] 8] Spravato is derived from ketamine and categorized by DEA as a Schedule III controlled substance.
Cannabis Law Report
JULY 9, 2021
Denver, Colorado was the first jurisdiction to decriminalize the use of psilocybin via ballot initiative in May 2019. Then, in November 2019, the FDA granted the designation to the nonprofit Usona Institute to study psilocybin’s effect on major depressive order, for which clinical trials are currently under way.
Cannabis Law Report
FEBRUARY 28, 2022
Clinical trials are producing promising results, creating enthusiasm for commercializing and patenting psychedelics. 12, 2019), [link] [ [link] ]. 1025, 1026 (2021) (reporting significant improvement of PTSD symptoms following treatment with MDMA in clinical trial); see also Alec J. Mitchell et al.,
Cannabis Law Report
JANUARY 14, 2020
601 , the “Medical Cannabis Research Act of 2019” H.R. 3797 , the “Medical Marijuana Research Act of 2019” H.R. 3884 , the “Marijuana Opportunity Reinvestment and Expungement Act of 2019” or the “MORE Act of 2019” Witnesses. Drug Enforcement Administration.
Expert insights. Personalized for you.
70 
Let's personalize your content